Insilico Medicine and ASKA Pharmaceutical Team Up for Women's Health Innovations

In a significant move to advance women's health, Insilico Medicine, a clinical-stage drug discovery firm, has formed a strategic partnership with ASKA Pharmaceutical, a company specializing in internal medicine including obstetrics and gynecology. This collaboration aims to uncover new therapeutic targets for challenging gynecologic conditions such as endometriosis, uterine fibroids, and adenomyosis by utilizing Insilico's cutting-edge AI-driven target identification technology, known as PandaOmics.

Addressing Critical Health Challenges

Gynecological diseases represent a considerable healthcare burden worldwide, impacting millions of women. According to the World Health Organization, there are approximately 190 million women affected by endometriosis, with uterine fibroids and adenomyosis affecting even larger groups. These conditions often co-exist, complicating treatment and diagnosis and necessitating innovative therapeutic approaches.

The partnership between Insilico and ASKA combines their respective strengths: ASKA's thorough knowledge of gynecological therapy and Insilico’s prowess in biological analytics powered by AI. This fusion aims to meet the pressing medical needs of hundreds of millions of women globally.

Leveraging Advanced AI for Drug Discovery

Under this agreement, Insilico Medicine will utilize PandaOmics to identify and evaluate disease hypotheses. Meanwhile, ASKA will validate the targets that are predicted by AI to have high potential for success in drug development. The initiative is spearheaded by Dr. Frank Pun, who leads the Target Discovery team at Insilico’s Hong Kong operations.

Recently, this team launched Target Identification Pro (TargetPro), a sophisticated AI-driven framework designed to streamline the process of discovering therapeutic targets by integrating diverse data into models tailored to specific diseases. TargetPro not only enhances predictive accuracy for targets likely to progress into clinical stages, but it also identifies promising new candidates optimized for swift preclinical testing.

Dr. Pun emphasized the importance of this collaboration, stating, "The preclinical validation of our AI-nominated targets for endometriosis illustrates how AI can provide actionable insights into the complex biology surrounding women's health. With our latest disease-specific models, we are eager to assist ASKA in developing the next wave of treatment options for women globally."

Dr. Shuzo Watanabe from ASKA echoed this sentiment, expressing excitement about the collaborative effort, "We are thrilled to partner with Insilico Medicine. Our goal is to expedite the drug discovery process by integrating AI throughout our R&D phases, aiming to uncover high-quality and promising drug discovery targets swiftly."

A Robust Partnership with Proven Foundations

Historically, ASKA has been an advocate for utilizing Insilico’s AI software, and this expanded collaboration aims to deepen the application of these technologies in addressing the multifaceted biological challenges associated with conditions like endometriosis, uterine fibroids, and adenomyosis. The ambition is to pave a clear path for the innovations needed in women’s health.

As the partnership unfolds, both Insilico Medicine and ASKA Pharmaceutical are committed to pushing the boundaries of what's possible in women's healthcare. By combining advanced technology with expert clinical knowledge, they are positioned to make significant strides in improving the quality of life for women suffering from these challenging conditions.

About Insilico Medicine

Insilico Medicine is at the forefront of biotechnology, leveraging artificial intelligence and automation to accelerate drug discovery and innovation in life sciences. Since its listing on the Hong Kong Stock Exchange (stock code: HKEX 03696) at the end of 2025, Insilico continues to drive advancements across various medical fields, including oncology, immunology, and metabolic disorders.

For more information on Insilico Medicine, visit www.insilico.com.

About ASKA Pharmaceutical

ASKA Pharmaceutical dedicates itself to the advancement of healthcare and medicine through innovative product development, particularly in internal medicine, obstetrics, and gynecology. Its mission is to respond to social needs and enhance health outcomes through its pharmaceutical contributions.

To learn more, visit ASKA Pharmaceutical.